Clinical Trials Browser

Has results × Paclitaxel × Sarcoma × Clear all

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT03395080 2025-08-01

P204

Phase 2 Completed

111 enrolled 22 charts

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT03206177 2024-08-07

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Phase 1 Completed

26 enrolled 13 charts

Carcinosarcoma

NCT01367301 2023-08-21

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Phase NA Terminated

14 enrolled 5 charts

GynecologicSarcoma

Stage IA Uterine Sarcoma

NCT02212015 2022-03-22

EVA

Phase 2 Terminated

26 enrolled 16 charts

Hemangiosarcoma

NCT00954174 2021-09-30

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3 Unknown

637 enrolled 18 charts

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00112489 2018-09-25

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Phase 2 Completed

55 enrolled 6 charts

Sarcoma